{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Dermatologic Adverse Event Management', 'SKIN EVENTS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Grade 1-2', 'Symptomatic treatment should be given such as', 'topical glucocorticosteroids (eg, betamethasone', 'Dermatitis', 'exfoliative', '0.1% cream or hydrocortisone 1%) or urea-', 'Erythema', 'containing creams in combination with oral', 'multiforme', 'No change in dose', 'antipruritics (eg, diphenhydramine HCI or', 'Stevens-Johnson', 'syndrome', 'hydroxyzine HCI).', 'Toxic epidermal', 'Treatment with oral steroids is at investigator', 'necrolysis', 'discretion for Grade 2 events.', 'Grade 3', 'Consider dermatology consultation and biopsy for', 'All attempts should', 'confirmation of diagnosis.', 'be made to rule out', 'If considered to be', 'immune related,', 'Treatment with oral steroids is recommended,', 'other causes such as', '>Grade 3 or result in', 'dose modification', 'hold REGN2810', 'starting with 1 mg/kg prednisone or equivalent', 'metastatic disease,', 'or discontinuation:', 'once per day or dexamethasone 4 mg four times', 'infection, or allergic', 'Pruritus, Rash', 'Rash generalized', 'orally daily. When symptoms improve to Grade 1', 'dermatitis.', 'Rash maculo-papular', 'or less, steroid taper should be started and', 'continued over no less than 4 weeks.', 'Dermatology consultation and consideration of', 'biopsy and clinical dermatology photograph.', 'Grade 4', 'Permanently', 'Initiate steroids at 1-2 mg/kg prednisone or', 'discontinue REGN2810', 'equivalent. When symptoms improve to grade 1', 'or less, steroid taper should be started and', 'continued over no less than 4 weeks.', 'Regeneron Pharmaceuticals, Inc.', 'Page 128 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Hepatitis Adverse Event Management', 'Hepatitis', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Withhold REGN2810 if', 'there is a treatment-', 'emergent concurrent', 'elevation of ALT and', 'Monitor liver function tests more frequently until', 'Grade 1-2', 'bilirubin that', 'returned to baseline values.', 'Hepatitis', 'corresponds to an', 'Hepatitis,', 'upward shift of 2 or', 'Autoimmune', 'more grades in both', 'parameters.', 'All attempts should be', 'made to rule out other', 'causes such as', 'metastatic disease,', 'progressive liver', 'Consider appropriate consultation and liver biopsy to', 'disease, viral hepatitis,', 'establish etiology of hepatic injury, if necessary.', 'alternative drug', 'Treat with high-dose IV glucocorticosteroids for 24-48', 'toxicity, infectious', 'hours. When symptoms improve to grade 1 or less, a', 'causes and/or', 'Discontinue', 'steroid taper with dexamethasone 4 mg every 4 hours', 'myositis.', 'REGN2810 when AST', 'or prednisone at 1-2 mg/kg should be started and', 'continued over no less than 4 weeks.', 'Grade 3-4', 'or ALT >5.0 times ULN', 'If serum transaminase levels do not decrease 48 hours', 'and/or total bilirubin', 'after initiation of systemic steroids, oral', '>3.0 times ULN.', 'mycophenolate mofetil 500 mg every 12 hours may be', 'given. Infliximab is not recommended due to its', 'potential for hepatotoxicity.', 'Several courses of steroid tapering may be necessary as', 'symptoms may worsen when the steroid dose is', 'decreased', 'Regeneron Pharmaceuticals, Inc.', 'Page 129 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}